Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-GM-CSF/CSF2 Antibody (6J807) is a Rabbit antibody targeting GM-CSF/CSF2. Anti-GM-CSF/CSF2 Antibody (6J807) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 μL | $94 | 7-10 days | |
100 μL | $270 | 7-10 days |
Description | Anti-GM-CSF/CSF2 Antibody (6J807) is a Rabbit antibody targeting GM-CSF/CSF2. Anti-GM-CSF/CSF2 Antibody (6J807) can be used in ELISA. |
Alias | GM-CSF, GMCSF, CSF2, colony stimulating factor 2 (granulocyte-macrophage) |
Ig Type | Monoclonal Rabbit IgG |
Clone | 6J807 |
Reactivity | Human |
Application | ELISA |
Recommended Dose | ELISA: 1:5000-1:10000 |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human GM-CSF / CSF2 (rh GM-CSF / CSF2; TMPY-02466; NP_000749.2; Ala18-Glu144). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Immunogen | Recombinant Human GM-CSF / CSF2 protein (TMPY-02466) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.